Created in 2001, the EFPIA College of Europe Award is designed to support students presenting a Master’s Thesis in an area of particular interest to the pharmaceutical industry. The winner is offered a 6-month stage at EFPIA, followed by a 6-month stage in one of EFPIA’s member associations or companies.
The criteria applied for the appraisal of submissions include: comprehensiveness, coherence of argumentation,introduction of new dimensions and understanding of fundamental issues.
Alejandro Sanchez Frias - Laureat - EFPIA College of Europe Award 2016
"Back to the Garden of the Hesperides? Patent Rights, Competition Law and Human Stem Cells"
Claudia Calvi - Laureat - EFPIA College of Europe Award 2015
“Cross Border Healthcare and Directive 2011/24: a Follow-Up”
Ludivine Blanc - Laureat - EFPIA College of Europe Award 2014
"The Pharmaceutical Industry in a Global Economy: What Drives EU Exports of Pharmaceuticals Overseas"
Elise Melon - Laureat - EFPIA College of Europe Award 2012
"Patents, Competition Law and Open Innovation: A Study of "Global Patent Warming"
This paper deals with the “global patent warming” phenomenon and the increasing concerns it is raising, from the perspectives of the patent system, competition law and the new open innovation paradigm. “Global patent warming” is indeed a major challenge today: patent applications are increasing, the number of patents granted is increasing, pendency volumes are increasing. The phenomenon has grown to an extent such as to drive the patent system close to the burnout and to heavily question its efficiency and legitimacy. Because global patent warming, by the issues it raises, is largely symptomatic of the patent system perpetual crisis, understanding this phenomenon is the key to understand what is today at stake withthe patent system and to think about what the ways forward are.
Áine Mariga - Laureat - EFPIA College of Europe Award 2011
"Patent Settlements in the EU Pharmaceutical Industry - A Legal Analysis"
This paper examines reverse settlement payments concluded between pharmaceutical companies that have been highlighted as potentially problematic by the European Commission’s recent sector inquiry. These payments usually occur as part of settlement agreements in the framework of challenges to patent validity. A patent challenge may be settled with an undertaking not to challenge or compete against the patent in return for compensation. The concern is that these agreements may constitute violations of Article 101 TFEU in so far as payment is made in return for a delay in generic market entry beyond the scope of the patent that serves to restrict competition.
Cristian Bolognini - Laureat - EFPIA College of Europe Award 2009
"Limiting Parallel Trade of Drugs and Article 82 - What role for innovation and efficiencies as justifications after the ECJ Decision in Sot. Lelos Kai Sia?"
With its decision in Sot. Lelos Kai Sia, the ECJ brought a bit of clarity into the relationship between Article 82 and unilateral behaviours aimed at limiting parallel trade of drugs. The ECJ held that a dominant pharmaceutical company which refuses to fully supply extraordinary orders of its existing wholesalers does not breach Article 82 since this refusal can be seen as a reasonable and proportionate measure to protect its legitimate commercial interests. This paper will therefore discuss this solution in order to verify whether it can be considered a solid precedent or rather a “shortcut” taken by the ECJ to avoid complex economic analysis which it was still not ready to embark on.
Ingrid Liedorp - Laureate - EFPIA College of Europe Award 2008
"An Economic Perspective on Price Discrimination. Where do we go after GlaxoSmithKline?"
The Thesis focuses on specific aspects of economic theory and EU institutions' doctrine, leading to a line of argumentation in support of case-by-case market analysis. In this respect, the thesis provides synthesis of how economic welfare analysis could apply to pharmaceutical markets, limited to two markers: price discriminationand parallel trade.
Edith Frénoy - Laureate - EFPIA College of Europe Award 2007 Winner
"Market entry of Generic Drugs before Patent expiration – what effect on Competition?"
The Thesis focuses on possibilities for generic medicines to enter the market before patent expiration, and the consequences on competition and consumers benefit. Analysis includes an assessment on whether or not the proposed remedies from European authorities to restore competition on the pharmaceutical markets are enough, and whether or not some other measures could or should be implemented.
Teresa Lorca Morales - Second ex æquo - EFPIA College of Europe Award 2007
"Merger Control in the Pharmaceutical Sector and the Innovation Market Assessment. European Analysis in Practice and differences with the American Approach"
Thomas Kostera - Second ex æquo - EFPIA College of Europe Award 2007
"Unwelcome Europeanization – The Development of European cross-border Patient Mobility"
Previous EFPIA Awards Winners
- The EU's Contribution to Global Governance: The Case of Global Infectious Diseases - Thesis presented by Oliver WIECHOCZEK for the degree of Master of European Studies at the College of Europe (June 2006)
- Access to Medicines in Developing Countries - Compulsory Licensing for Export: A Significant Step Forward or Merely Symbolic? - Thesis presented by Lorraine Gallagher (May 2005)
- The Cost of HIV/Aids, Tuberculosis and Malaria Epidemics for the European Union - Thesis presented by Nicolas Dross (May 2004)
- Patent Protection of Pharmaceuticals in the Context of EU Enlargement - Retrospective Analysis of the Community Approach towards Central and Eastern European Countries - Thesis presented by Nora Tosics (May 2003)
- Differential pricing and the problem of Access to essential Medicines in Developing Countries -Thesis presented by Emma Squire (June 2002)